STADA collaboration expands in Germany

28 Nov, 2019, 08:30

Regulatory information

Enzymatica and its German partner STADA have entered into an agreement for the marketing and sales of a new mouth spray for the German market. The new product is based on the same barrier technology as previous products from Enzymatica. STADA has placed a first order amounting to SEK 2,3 million. STADA expects to launch the mouth spray in the beginning of 2020.

“We are very pleased of STADA launching a mouth spray intended for their own home market. It is very positive that the German consumer gets a chance to use our products,” says Fredrik Lindberg, CEO of Enzymatica.

The information in this press release is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.30 CET on 28 November, 2019.

For more information, please contact:

Fredrik Lindberg, CEO Enzymatica AB
Phone: +46 (0)708-86 53 70 | Email: fredrik.lindberg@enzymatica.com

Carl-Johan Wachtmeister, Communication manager Enzymatica AB
Phone: +46 (0)0701-88 50 21 | Email: carl-johan.wachtmeister@enzymatica.com

About Enzymatica AB

Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily

conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company’s first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in about ten markets. The strategy is to continue to grow by developing more health care products and strengthening the company’s position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North Growth Market. For more information, visit: www.enzymatica.com and www.enzymatica.se/en/section/media/press-releases

Enzymatica’s certified adviser is Erik Penser Bank.För mer information, kontakta:

Fredrik Lindberg, VD Enzymatica AB
Tel: 0708-86 53 70 | E-post: fredrik.lindberg@enzymatica.com

Om Enzymatica AB

Enzymatica AB är ett life science-bolag som utvecklar och säljer medicintekniska produkter mot infektionsrelaterade sjukdomar. Produkterna är baserade på en barriärteknologi, som inkluderar marina enzymer. Bolagets första produkt är ColdZyme® Munspray som kan förhindra förkylning, och kan förkorta sjukdomsperioden. Produkten har lanserats på ett tiotal marknader. Strategin är att fortsätta växa genom att stärka positionen på befintliga marknader och expandera till fler geografiska marknader via etablerade partners. Bolaget har huvudkontor i Lund och är listat på Nasdaq First North. För mer information, besök: www.enzymatica.se.

Enzymaticas Certified Adviser är Erik Penser Bank.

Phone: +46 (0)8 463 83 00. Email: certifiedadviser@penser.se